公开(公告)号：US12023348B2

公开(公告)日：2024-07-02

申请号：US15569407

申请日：2016-04-26

Applicant: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Inventor： Ofer Sarig ,  Eli Sprecher

IPC: A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

CPC classification number: A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

Abstract: A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:



a compound represented by Formula I:








or a pharmaceutically acceptable salt thereof,



a compound represented by Formula II:










and a compound represented by Formula III:








wherein the variables in Formulae I, II and III are as defined in the specification.

公开(公告)号：US20240180962A1

公开(公告)日：2024-06-06

申请号：US18285637

申请日：2022-04-06

Applicant: Artiva Biotherapeutics, Inc. ,  GC CELL CORPORATION

Inventor： Sungyoo CHO ,  Yu Kyeong HWANG ,  Eunji CHOI ,  Miyoung JUNG ,  Hoyong LIM ,  Eunsol LEE ,  Hansol KIM ,  Peter FLYNN ,  Jason B. LITTEN ,  Thomas James FARRELL ,  John Kin Chuan LIM ,  Mili MANDAL

IPC: A61K35/17 ,  A61K31/688 ,  A61K31/7076 ,  A61K38/20 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K31/688 ,  A61K31/7076 ,  A61K38/2013 ,  A61K39/39558 ,  C07K16/2887 ,  C12N5/0646 ,  A61K2039/545 ,  C07K2317/732 ,  C12N2501/23 ,  C12N2501/515 ,  C12N2502/1114

Abstract: Provided herein are, among other things, methods for treating a patient suffering from a CD20+ cancer.

公开(公告)号：US20240139120A1

公开(公告)日：2024-05-02

申请号：US18478684

申请日：2023-09-29

Applicant: The Cleveland Clinic Foundation

Inventor： Stanley L. Hazen ,  Jonathan Mark Brown

IPC: A61K31/045 ,  A61K31/133 ,  A61K31/14 ,  A61K31/205 ,  A61K31/4164 ,  A61K31/5375 ,  A61K31/616 ,  A61K31/675 ,  A61K31/688 ,  A61K31/7036 ,  A61K31/7105 ,  A61K35/741 ,  A61P3/04

CPC classification number: A61K31/045 ,  A61K31/133 ,  A61K31/14 ,  A61K31/205 ,  A61K31/4164 ,  A61K31/5375 ,  A61K31/616 ,  A61K31/675 ,  A61K31/688 ,  A61K31/7036 ,  A61K31/7105 ,  A61K35/741 ,  A61P3/04 ,  A61K45/06

Abstract: Provided herein are compositions, systems, and methods for causing weight loss and treating and/or preventing a disease or condition, such as obesity, diabetes, and cancer, with an agent or procedure that inhibits the TMA/FMO3/TMAO pathway in a subject.

公开(公告)号：US20230263179A1

公开(公告)日：2023-08-24

申请号：US18172992

申请日：2023-02-22

Applicant: Beijing Sanyuan Foods Co., Ltd.

Inventor： Lijun CHEN ,  Jingyao Chen ,  Junying Zhao ,  Yan Liu ,  Qian Liu ,  Bin Liu ,  Weicang Qiao

IPC: A23C9/152 ,  A23C9/16 ,  A23C3/02 ,  A61K38/17 ,  A61K38/38 ,  A61K38/40 ,  A61K31/702 ,  A61K31/715 ,  A61K31/7008 ,  A61K31/688 ,  A61K31/7028 ,  A61K31/685 ,  A61K31/683 ,  A61K31/231 ,  A61K31/232 ,  A61K35/20 ,  A61P1/14

CPC classification number: A23C9/1526 ,  A23C9/16 ,  A23C9/1528 ,  A23C3/02 ,  A61K38/1709 ,  A61K38/38 ,  A61K38/40 ,  A61K38/1735 ,  A61K31/702 ,  A61K31/715 ,  A61K31/7008 ,  A61K31/688 ,  A61K31/7028 ,  A61K31/685 ,  A61K31/683 ,  A61K31/231 ,  A61K31/232 ,  A61K35/20 ,  A61P1/14

Abstract: An infant formula milk powder is rich in milk fat globule membrane protein, phospholipids, and oligosaccharides. A preparation method includes using raw cow milk as raw material, cleaning and pre-sterilizing raw cow milk, adding MFGM-rich whey protein powder, α-lactalbumin powder, galactooligosaccharides, polyfructoses and other ingredients into the pre-sterilized raw cow milk, and performing pre-sterilization, homogenization, sterilization, concentration, and spray drying. By means of formula adjustment, the contents of biologically active substances having special functional components such as MFGM-protein, lactoferrin, α-lactalbumin, total galactooligosaccharide, total polyfructose, sialic acid, total phospholipid, sphingomyelin, lecithin, phosphatidylserine, phosphatidylethanolamines, phosphatidylinositol, ganglioside, triglyceride and diglyceride in the infant formula milk powder are increased, thereby facilitating the colonization of probiotics in the intestinal microbiota of an infant, especially significantly enriching lactic acid bacteria in an intestinal tract, while reducing unclassified bacterial family and other miscellaneous bacteria.

公开(公告)号：US20180258097A1

公开(公告)日：2018-09-13

申请号：US15888749

申请日：2018-02-05

Applicant: Gilead Sciences, Inc.

Inventor： Elizabeth M. Bacon ,  Elbert Chin ,  Jeromy J. Cottell ,  Ashley Anne Katana ,  Darryl Kato ,  John O. Link ,  Nathan Shapiro ,  Teresa Alejandra Trejo Martin ,  Zheng-Yu Yang

IPC: C07D487/08 ,  A61K45/06 ,  A61K31/55 ,  A61K31/685 ,  A61K31/688 ,  A61P31/18 ,  A61K31/52 ,  A61K31/553

CPC classification number: C07D487/08 ,  A61K31/52 ,  A61K31/55 ,  A61K31/553 ,  A61K31/685 ,  A61K31/688 ,  A61K45/06 ,  A61P31/18 ,  C07C243/28 ,  C07C275/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D471/08 ,  C07D487/10 ,  C07D491/04

Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

公开(公告)号：US10034891B2

公开(公告)日：2018-07-31

申请号：US15151740

申请日：2016-05-11

Applicant: METABASIS THERAPEUTICS, INC.

Inventor： K. Raja Reddy ,  Jeff Stebbins ,  Serge H. Boyer ,  Mark D. Erion ,  Scott J. Hecker ,  Nicholas Brian Raffaele ,  Brett C. Bookser ,  Venkat Reddy Mali

IPC: A01N43/82 ,  A61K31/41 ,  A61K31/675 ,  A61K31/542 ,  A61K31/52 ,  A61K31/662 ,  A61K31/665 ,  A61K45/06 ,  C07D473/16 ,  C07D473/34 ,  C07D473/40 ,  C07F9/30 ,  C07F9/32 ,  C07F9/653 ,  C07F9/6561 ,  C07F9/6574 ,  C07F9/48 ,  C07F9/655 ,  A61K31/683 ,  A61K31/688 ,  C07F9/40

CPC classification number: A61K31/675 ,  A61K31/52 ,  A61K31/542 ,  A61K31/662 ,  A61K31/665 ,  A61K31/683 ,  A61K31/688 ,  A61K45/06 ,  A61P3/04 ,  A61P3/10 ,  C07D473/16 ,  C07D473/34 ,  C07D473/40 ,  C07F9/303 ,  C07F9/3229 ,  C07F9/40 ,  C07F9/48 ,  C07F9/65312 ,  C07F9/6552 ,  C07F9/6561 ,  C07F9/65616 ,  C07F9/65742 ,  A61K2300/00

Abstract: The invention pertains to the use of compounds represented by the formula, Q-G1-G2-G3-G4-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

公开(公告)号：US20180168215A1

公开(公告)日：2018-06-21

申请号：US15386403

申请日：2016-12-21

Applicant: Mead Johnson Nutrition Company

Inventor： Chenzhong Kuang ,  Yan Xiao ,  Shay Phillips ,  Sarah Maria ,  Eric A.F. van Tol ,  Colin Rudolph ,  Dirk Hondmann

IPC: A23L33/00 ,  A23L33/135 ,  A23L33/12 ,  A23L33/10 ,  A61K31/70 ,  A61K38/40 ,  A61K31/047 ,  A61K35/741 ,  A61K31/202 ,  A61K31/19 ,  A61K31/688 ,  A61K31/716 ,  A61K35/744

CPC classification number: A23L33/40 ,  A23L33/10 ,  A23L33/12 ,  A23L33/125 ,  A23L33/135 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/047 ,  A61K31/19 ,  A61K31/202 ,  A61K31/688 ,  A61K31/70 ,  A61K31/716 ,  A61K35/741 ,  A61K35/744 ,  A61K35/747 ,  A61K38/40 ,  A61P25/28 ,  A61K2300/00

Abstract: Provided are nutritional compositions containing inositol. Further disclosed are methods for promoting optimal and functional synaptic development in a target subject via administering the nutritional composition containing inositol to the target subject. Further provided are methods for promoting brain development and overall brain health and function in a target subject.

公开(公告)号：US20170182121A1

公开(公告)日：2017-06-29

申请号：US15398219

申请日：2017-01-04

Applicant: Cerenis Therapeutics Holding S.A.

Inventor： Jean-Louis DASSEUX

IPC: A61K38/17 ,  A61K31/688 ,  A61K31/685 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K38/1709 ,  A61K9/0095 ,  A61K9/127 ,  A61K9/1275 ,  A61K31/685 ,  A61K31/688 ,  A61K38/00 ,  A61K49/0008 ,  C07K14/775

Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.

公开(公告)号：US09585936B2

公开(公告)日：2017-03-07

申请号：US14974055

申请日：2015-12-18

Applicant: The Regents of the University of California ,  Schepens Eye Research Institute

Inventor： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC: A61K38/00 ,  A61K38/14 ,  A61K9/00 ,  A61K31/568 ,  A61K31/715 ,  A61K38/13 ,  A61K38/18 ,  A61K38/17 ,  A61K45/06 ,  A61K31/728 ,  A61K31/685 ,  A61K31/688 ,  A61K47/02 ,  A61K47/24

CPC classification number: A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract translation: 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界缺乏症，与之相关的症状，或与眼表面相关或引起不适的不期望状况。 本发明的药物组合物包含悬浮在眼睛可接受的载体中的人PRG4蛋白或其润滑片段。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。

公开(公告)号：US09567388B2

公开(公告)日：2017-02-14

申请号：US14085685

申请日：2013-11-20

Applicant: Cerenis Therapeutics Holding S.A.

Inventor： Jean-Louis Dasseux

IPC: C07K14/775 ,  A61K31/685 ,  A61K9/127 ,  A61K49/00 ,  A61K31/688 ,  A61K38/17 ,  A61K38/00

CPC classification number: A61K38/1709 ,  A61K9/0095 ,  A61K9/127 ,  A61K9/1275 ,  A61K31/685 ,  A61K31/688 ,  A61K38/00 ,  A61K49/0008 ,  C07K14/775

Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.

Abstract translation: 本公开提供了带电荷的脂蛋白复合物，其包括作为一种组分的带负电荷的磷脂，其预期赋予复合物改善的治疗性质。